Nano2Brain
The proposed invention provides a nanotechnological based platform, particularly a nanostructured lipid carrier (NLC) with a particle size lower than 200 nm, encapsulating a combination of agents aiming at brain tumor therapy. This is achieved through, but not limited to coupling tumor-specific ligands on the surface of the nanosystem to preferentially and/or specifically target cell populations such as tumor cells. Thus, the platform is able, but not limited, to preferentially deliver therapeutic and/or diagnostic agents, alone or in combination, through the blood brain-barrier (BBB) to the brain, at the intracellular level, by receptor-mediated endocytosis. This system mediates efficient intracellular release of the encapsulated agents, increasing the concentration of the payload at the target site and reducing agent-associated adverse side-effects. Consequently, the strategy adopted by the invention promotes an improvement of the safety and efficiency for glioblastoma therapy and/or diagnostic.
